< back to all PPMI Presentations

Relationship between Serum Urate and Clinical Features in Early Parkinsons Disease: PPMI Baseline Data

Constantinescu, R; Jennings, D; Foster, E.D; Auinger, P; Coffey, C.S; Marerk, K; the Parkinson\'s Progression Marker Initiative
 
2013-06-18
MDS: Sydney, Australia
Download Presentation: Urate-MDS poster June 10-2013.pdf
 
Abstract:
Objective:
To investigate serum urate (S-urate) levels and their relationship with clinical features at baseline in the early Parkinson's disease (PD) and healthy control (HC) cohort enrolled in the Parkinson Progression Marker Initiative (PPMI) study.
Background:
Previous studies found higher S-urate levels to be associated with a lower risk for developing PD [1] and with a slower rate of disease progression in PD.
Methods:
Cross-sectional sub-analysis of PPMI baseline data for the first 507 enrolled subjects (PD=343 [224 M, 119 F], HC=164 [100 M, 64 F]). S-urate was measured by a commercial laboratory (Covance). Cerebrospinal fluid (CSF) a-synuclein was analyzed using a commercially available ELISA. Clinical features were assessed per PPMI protocol. Two sample t-tests were used to assess the difference in mean S-urate between PD and HC subjects, adjusting for gender. Within PD subjects, the association of S-urate with other biomarkers and clinical variables was investigated using univariate linear regressions and correlations.
Results:
S-urate levels were not significantly different in PD (M 350.2+72.5, F 258.7±54.0) compared with HC subjects (M 343.7±63.7, F 270.5±50.3). In PD, there were no significant correlations between S-urate levels and clinical features, assessed using The Movement Disorder Society UPDRS part III, the Montreal Cognitive Assessment, and the Geriatric Depression Scale, or with CSF a-synuclein levels.
Conclusions:
According to these preliminary results using this simplified means analysis, there was no significant difference in baseline S-urate levels in PD subjects compared with HC. Baseline S-urate levels were not associated with various clinical features at early PD stages in the PPMI population. Additional, more detailed analyses are underway. [1] Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. American journal of epidemiology. 1996;144:480-4.